Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was down 5.3% on Thursday following insider selling activity. The company traded as low as $5.41 and last traded at $5.53. Approximately 1,098,403 shares changed hands during trading, an increase of 159% from the average daily volume of 424,423 shares. The stock had previously closed at $5.84.

Specifically, insider Jacques Dumas sold 7,167 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director L Patrick Gage bought 3,880 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were purchased at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The disclosure for this purchase can be found here. 5.50% of the stock is currently owned by insiders.

A number of equities analysts recently weighed in on TTPH shares. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average target price of $15.15.

The firm has a market cap of $301.31 and a price-to-earnings ratio of -1.88.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The firm had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. During the same period in the previous year, the company earned ($0.58) earnings per share. The company’s quarterly revenue was up 355.6% on a year-over-year basis. analysts anticipate that Tetraphase Pharmaceuticals Inc will post -2.88 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at $107,000. Brighton Jones LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at $108,000. Voya Investment Management LLC increased its holdings in shares of Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 3,104 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at $147,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at $162,000. Hedge funds and other institutional investors own 58.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.watchlistnews.com/tetraphase-pharmaceuticals-ttph-stock-price-down-5-3-after-insider-selling/1840771.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.